Virtual Reality Headset and Acceptability of Rectosigmoidoscopy in Ulcerative Colitis: a Randomised Controlled Trial (VIRTU)

Haemorrhagic rectocolitis is an inflammatory bowel disease that continuously affects the rectum and colon, with lesions that extend variably from the rectum into the upstream colon. This disease requires repeated assessment of both clinical activity (transcribed by the clinical Mayo score) and endoscopic activity. ACCEPT study showed that the acceptability of rectosigmoidoscopy is low, and the main determinants of this low acceptability were pain and bloating (51%) and embarrassment during the examination (30%).

Virtual reality headsets has analgesic and anxiolytic properties, thanks to specially designed virtual environments that apply different principles such as medical hypnosis, music therapy and cardiac coherence to enhance therapeutic action.

The aim of our project is to study the benefit of medical hypnosis provided by the use of a virtual reality headset in terms of tolerance of lower digestive endoscopy in patients with ulcerative colitis.

Study Overview

• Status: Recruiting
• Conditions: Haemorrhagic Rectocolitis
• Intervention / Treatment: Device: Virtual reality headset

Detailed Description

Haemorrhagic rectocolitis is an inflammatory bowel disease that continuously affects the rectum and colon, with lesions that extend variably from the rectum into the upstream colon.

This disease requires repeated assessment of both clinical activity (transcribed by the clinical Mayo score) and endoscopic activity. Assessment of mucosal healing is one of the therapeutic objectives defined in the STRIDE II consensus, and requires regular repeat endoscopic examinations in these patients.

The aim of the ACCEPT study, which involved administering a questionnaire to 916 patients with chronic inflammatory bowel disease, was to assess patients; acceptability and perceived usefulness of examinations designed to assess the activity of chronic inflammatory bowel disease. This study showed that the acceptability of rectosigmoidoscopy is low, and the main determinants of this low acceptability were pain and bloating (51%) and embarrassment during the examination (30%).

The dominant approaches to addressing this issue focus on replacing rectosigmoidoscopy with less invasive tools such as ultrasound and faecal calprotectin. However, rectosigmoidoscopy is still unavoidable, particularly for rectal forms (poor performance of ultrasound, low reliability of faecal calprotectin).

Virtual reality headsets are now part of our everyday lives. Developed as part of the neurosciences, they have applications in healthcare (pain care, dementia, post-traumatic stress disorder, etc.), occupational risk prevention and leisure (escape games, video games).

This device has analgesic and anxiolytic properties, thanks to specially designed virtual environments that apply different principles such as medical hypnosis, music therapy and cardiac coherence to enhance therapeutic action.

This approach has been evaluated in endoscopy, to improve the tolerance of colorectal cancer screening colonoscopies. A Chinese study (Liu et al, Clinical medicine 2022), which included 120 patients in a randomised trial comparing the virtual reality headset with a headset that was switched off, showed that the headset that was switched on made it possible to gain a median of 2 points on the pain scale, to reduce skin conductance (an indirect marker of nervousness) and to improve patient satisfaction. We hypothesise that the gain in SR would be the same, with an examination that is reputed to be less painful than colonoscopy without anaesthetic.

The aim of our project is to study the benefit of medical hypnosis provided by the use of a virtual reality headset in terms of tolerance of lower digestive endoscopy in patients with ulcerative colitis.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Clémentin GABORIAU; Phone Number: 0251446572; Email: clementin.gaboriau@ght85.fr

Study Locations

• France
  • La Roche Sur Yon, France, 85925
    • Recruiting
    • Centre Hospitalier Departemental Vendee
    • Principal Investigator: Morgane Amil
  • Nantes, France, 44000
    • Recruiting
    • Centre Hospitalier Universitaire Nantes
    • Principal Investigator: Michael COLLINS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged 18 or over with UC in the active phase or in remission of their disease
• Patient who has already undergone rectosigmoidoscopy without general anaesthetic
• Patient requiring rectosigmoidoscopy (with colonoscope and air insufflation) as part of routine care
• Patient able to follow the Clinical Investigation protocol and having given written informed consent to participate
• Patient affiliated to the social security system or entitled beneficiary

Exclusion Criteria:

• Patients with Crohn disease or indeterminate colitis
• Patients hospitalised with severe acute colitis, as defined by the truelove criteria.
• Patients with a stoma in place or with a history of colorectal resection.

• Patients with a contraindication to the use of the virtual reality headset:

  • Psychotic patients or patients diagnosed with psychiatric disorders
  • Patients with uncontrolled epilepsy
  • Patients with visual problems (lack of binocular vision, blindness) and/or hearing problems (deafness) that prevent them from using virtual reality.
• Patients taking part in another clinical research protocol having an impact on the objectives of the clinical investigation
• Patients already randomized in the clinical investigation
• Pregnant, parturient or breast-feeding patients
• Patients under guardianship, curatorship or deprived of their liberty
• Patient under activated protection mandate or family habilitation
• Patients under court protection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rectosigmoidoscopy with virtual reality headset	Device: Virtual reality headset; Use of a virtual reality headset during rectosigmoidoscopy
No Intervention: Rectosigmoidoscopy without a virtual reality headset

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain intensity measured on a visual analogue scale	Pain intensity measured on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (maximum intolerable pain) immediately after the examination.	Immediately after the examination.

Collaborators and Investigators

• Sponsor: Centre Hospitalier Departemental Vendee
• Investigators: Principal Investigator: Morgane AMIL, Centre Hospitalier Departemental Vendee

Study record dates

Study Major Dates

• Study Start (Actual): October 9, 2024
• Primary Completion (Estimated): April 9, 2027
• Study Completion (Estimated): April 9, 2027

Study Registration Dates

• First Submitted: October 7, 2024
• First Submitted That Met QC Criteria: October 7, 2024
• First Posted (Actual): October 9, 2024

Study Record Updates

• Last Update Posted (Actual): August 1, 2025
• Last Update Submitted That Met QC Criteria: July 31, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Haemorrhagic rectocolitis
• Additional Relevant MeSH Terms: Intestinal Diseases; Digestive System Diseases; Gastrointestinal Diseases; Rectal Diseases; Colonic Diseases; Gastroenteritis; Inflammatory Bowel Diseases; Sigmoid Diseases; Proctitis; Colitis; Colitis, Ulcerative; Proctocolitis
• Other Study ID Numbers: CHD23_0096

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No